Purple Biotech Ltd. Updates Company Presentation
Ticker: PPBT · Form: 6-K · Filed: Aug 19, 2024 · CIK: 1614744
Sentiment: neutral
Topics: company-update, investor-relations
TL;DR
Purple Biotech dropped a new investor deck, check it out.
AI Summary
On August 19, 2024, Purple Biotech Ltd. announced it has made an updated Company Presentation available on its website. This presentation is attached as Exhibit 99.1 to the filing.
Why It Matters
Investors can access the latest information and strategic overview directly from the company's updated presentation.
Risk Assessment
Risk Level: low — This filing is an informational update and does not contain material financial or operational changes.
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- August 19, 2024 (date) — Announcement date
- Exhibit 99.1 (document) — Attached presentation
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose is to announce that Purple Biotech Ltd. has made an updated Company Presentation available on its website.
When was the updated Company Presentation made available?
The updated Company Presentation was made available on August 19, 2024.
Where can investors find the updated Company Presentation?
The updated Company Presentation is available on Purple Biotech Ltd.'s website and is attached as Exhibit 99.1 to this filing.
What is the Commission File Number for Purple Biotech Ltd.?
The Commission File Number for Purple Biotech Ltd. is 001-37643.
What is the principal executive office address for Purple Biotech Ltd.?
The principal executive offices are located at 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.
Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-08-19 16:01:51
Filing Documents
- ea0211792-6k_purple.htm (6-K) — 14KB
- ea021179201ex99-1_purple.htm (EX-99.1) — 68KB
- ex99-1_001.jpg (GRAPHIC) — 110KB
- ex99-1_002.jpg (GRAPHIC) — 246KB
- ex99-1_003.jpg (GRAPHIC) — 94KB
- ex99-1_004.jpg (GRAPHIC) — 103KB
- ex99-1_005.jpg (GRAPHIC) — 107KB
- ex99-1_006.jpg (GRAPHIC) — 107KB
- ex99-1_007.jpg (GRAPHIC) — 132KB
- ex99-1_008.jpg (GRAPHIC) — 134KB
- ex99-1_009.jpg (GRAPHIC) — 118KB
- ex99-1_010.jpg (GRAPHIC) — 151KB
- ex99-1_011.jpg (GRAPHIC) — 105KB
- ex99-1_012.jpg (GRAPHIC) — 134KB
- ex99-1_013.jpg (GRAPHIC) — 113KB
- ex99-1_014.jpg (GRAPHIC) — 96KB
- ex99-1_015.jpg (GRAPHIC) — 107KB
- ex99-1_016.jpg (GRAPHIC) — 98KB
- ex99-1_017.jpg (GRAPHIC) — 107KB
- ex99-1_018.jpg (GRAPHIC) — 106KB
- ex99-1_019.jpg (GRAPHIC) — 127KB
- ex99-1_020.jpg (GRAPHIC) — 92KB
- ex99-1_021.jpg (GRAPHIC) — 84KB
- ex99-1_022.jpg (GRAPHIC) — 117KB
- ex99-1_023.jpg (GRAPHIC) — 109KB
- ex99-1_024.jpg (GRAPHIC) — 142KB
- ex99-1_025.jpg (GRAPHIC) — 132KB
- ex99-1_026.jpg (GRAPHIC) — 113KB
- ex99-1_027.jpg (GRAPHIC) — 107KB
- ex99-1_028.jpg (GRAPHIC) — 121KB
- ex99-1_029.jpg (GRAPHIC) — 93KB
- ex99-1_030.jpg (GRAPHIC) — 88KB
- ex99-1_031.jpg (GRAPHIC) — 134KB
- ex99-1_032.jpg (GRAPHIC) — 92KB
- ex99-1_033.jpg (GRAPHIC) — 118KB
- ex99-1_034.jpg (GRAPHIC) — 95KB
- ex99-1_035.jpg (GRAPHIC) — 95KB
- ex99-1_036.jpg (GRAPHIC) — 76KB
- ex99-1_037.jpg (GRAPHIC) — 110KB
- ex99-1_038.jpg (GRAPHIC) — 110KB
- ex99-1_039.jpg (GRAPHIC) — 110KB
- ex99-1_040.jpg (GRAPHIC) — 129KB
- ex99-1_041.jpg (GRAPHIC) — 115KB
- ex99-1_042.jpg (GRAPHIC) — 120KB
- ex99-1_043.jpg (GRAPHIC) — 37KB
- ex99-1_044.jpg (GRAPHIC) — 81KB
- ex99-1_045.jpg (GRAPHIC) — 80KB
- ex99-1_046.jpg (GRAPHIC) — 119KB
- ex99-1_047.jpg (GRAPHIC) — 109KB
- ex99-1_048.jpg (GRAPHIC) — 75KB
- ex99-1_049.jpg (GRAPHIC) — 126KB
- ex99-1_050.jpg (GRAPHIC) — 93KB
- ex99-1_051.jpg (GRAPHIC) — 89KB
- ex99-1_052.jpg (GRAPHIC) — 134KB
- ex99-1_053.jpg (GRAPHIC) — 123KB
- 0001213900-24-070677.txt ( ) — 8089KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. August 19, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2